跳至主要内容
临床试验/EUCTR2011-002233-19-SE
EUCTR2011-002233-19-SE进行中(未招募)1 期

Antiplatelet effects of once versus twice daily dosing of aspirin after coronary artery bypass grafting

Karolinska Institute0 个研究点目标入组 42 人开始时间: 2011年9月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Stable CAD patients scheduled to undergo elective CABG surgery
  • - Willing to participate and able to provide informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • - Patients taking drugs other than aspirin that are known to influence platelet function, including nonsteroidal anti-inflammatory drugs (NSAIDs, including COX-2 selective anti-inflammatory drugs), GPIIbIIIa inhibitors, clopidogrel, dipyridamole, warfarin or acenocoumarol within 7 days of enrolment
  • - Hemorrhagic diathesis or known platelet dysfunction
  • - Patients with chronic renal failure requiring dialysis
  • - Patients with a platelet count outside the 100 000 to 450 000/µL range
  • - Patients with severe anaemia (Haemoglobin < 8g/dl)

研究者

发起方
Karolinska Institute

相似试验